RT Journal Article
SR Electronic
T1 Inhaled nitric oxide use in COVID19-induced hypoxemic respiratory failure
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.19.21262314
DO 10.1101/2021.08.19.21262314
A1 Giri, Abhishek R.
A1 Yarrarapu, Siva Naga S.
A1 Kaur, Nirmaljot
A1 Hochwald, Alex
A1 Crook, Julie
A1 Helgeson, Scott
A1 Harrison, Michael F.
A1 Patel, Neal
A1 Guru, Pramod K.
A1 Lowman, Philip
A1 Moreno-Franco, Pablo
A1 Lee, Augustine
A1 Sanghavi, Devang K.
YR 2021
UL http://medrxiv.org/content/early/2021/08/21/2021.08.19.21262314.abstract
AB Introduction Nitric Oxide (NO) is an endogenous vasodilator that is synthesized by the vascular endothelium. Due to its vasodilatory effect and short half-life, the use of NO as an exogenous inhaled medication (iNO) to target the pulmonary vasculature, in conditions with increased pulmonary vascular resistance, has been studied.The use of iNO in patients with ARDS secondary to COVID-19 has therapeutic importance in improving oxygenation. It also has potential anti-viral, anti-inflammatory, and anti-thrombotic properties.Herein, we want to share our experience of use of iNO in hypoxemic respiratory failure secondary to COVID 19 pneumonia. We hypothesized that iNO may be beneficial at preventing intubation, decreasing invasive mechanical ventilation duration, and consequently improve outcomes including hospital mortality.Methods This is a descriptive hypothesis generating study of patients admitted for COVID-19 pneumonia who received iNO for hypoxemic respiratory failure, at a single tertiary care center. We collected information on patient demographics, co-morbidities, iNO treatment, need for intubation, arterial blood gas analysis, laboratory values, hospital length of stay, and mortality. Patients were divided into two groups based on the timing of iNO administration: group 1 - “pre-intubation” (i.e. iNO started at least 1 day prior to endotracheal intubation, if any) and group 2 - “post-intubation” (i.e. iNO started on the same day as or after endotracheal intubation and mechanical ventilation).Result A total of 45 (group 1, n=26 [57.8%] vs group2, n=19 [42.2%]) COVID 19 patients who had iNO use. The mean time from hospital admission to iNO administration(days) in group 1 was 2.1 (±1.8) vs 4.2 (±5.9) in group 2. The mean hospital length of stay from the beginning of iNO treatment until discharge or death was 18.3 vs 26.2 days, with 8 deaths (30.8%) vs 9 deaths (47.4%) in group 1 vs group 2, respectively.Discussion Our study is unable to demonstrate comparably outcomes benefit of iNO. Although there was a trend towards decreased need for invasive mechanical ventilation in group 1[Only 11 (42.3%) patients were intubated out of 26 who received iNO early after hospital admission (2.3 days)], no statistical significance could be achieved because of small sample size.Our study demonstrated that iNO administration pre-intubation did not appear harmful and appears to be safe, complementary to HFNC, signalling the domain where systematic investigation is required to confirm or not the potential for iNO to improve patient outcomes in the management of COVID 19-induced hypoxemic respiratory failure.Conclusion This study showcases the potential benefit of early pre-intubation use of iNO in COVID patients with hypoxemic respiratory failure. This study could conclusively form the basis for a prospective trial and could have a tremendous impact in improving patient outcomes.HighlightsInhaled nitric oxide can be used in the treatment COVID 19 induced hypoxemic respiratory failure.Inhaled nitric oxide use can lower the burden on overwhelmed medical system.Inhaled nitric oxide use may lower the need for intubation and subsequent invasive mechanical ventilation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Mayo Clinic Institutional review board has exempted this retrospective chart review study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe would like to declare that all data referred to in the manuscript is available with us.iNO(Inhaled nitric oxide)ICU(Intensive care unit)SOFA(Sequential Organ Failure Assessment)SD(Standard Deviation)